Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1671858 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $5.67Day −1.56%Mkt cap $563M1Y −69.1%Off 52W high −69.6%Vol (1Y) 71.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 927 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest22.8% of sh out |
| Days to cover15.3d |
| 13F net flow (QoQ)+8.47% |
| Top-10 13F concentration65.0% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$99.0M |
| Earnings (TTM)-$198.0M |
| ROE−92.3% |
| Net margin−203.3% |
| Debt / equity0.84× |
| Sales growth 3Y300.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−51.3% |
| 1Y−69.1% |
| 3Y−20.1% |
| Since incept. (ann.)−1.8% |
Total return through 2026-07-28 · series begins 2022-11-09. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)71.3% |
| Ann. volatility (3Y)74.1% |
| Sharpe (1Y)−1.31 |
| Sharpe (3Y)0.34 |
| Max drawdown (1Y)−69.1% |
| Max drawdown (3Y)−69.1% |
| Beta (3Y vs SPY)2.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.9M | $87M | 10.94% | +0.0% |
| ORBIMED ADVISORS LLC | 8.3M | $67M | 8.35% | +0.0% |
| Rubric Capital Management LP | 8.0M | $64M | 8.06% | +29.0% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 7.5M | $60M | 7.56% | +0.0% |
| MILLENNIUM MANAGEMENT LLC | 6.0M | $48M | 6.02% | +88.8% |
| BlackRock, Inc. | 5.0M | $40M | 5.05% | −1.4% |
| Aberdeen Group plc | 4.1M | $33M | 4.14% | +15.7% |
| SR One Capital Management, LP | 4.0M | $32M | 4.04% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.61 | — | $22.7M | +184.5% |
| 2025-12-31 | 2026-03-09 | — | — | $28.1M | −67.6% |
| 2025-09-30 | 2025-11-10 | −$0.52 | — | $32.5M | +1471.6% |
| 2025-06-30 | 2025-08-13 | −$0.46 | — | $15.7M | +3043.4% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 86% · Non Us 14%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
